Tags

Type your tag names separated by a space and hit enter

Binimetinib plus encorafenib for metastatic melanoma.
Aust Prescr 2019; 42(5):168AP

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31631932

Citation

"Binimetinib Plus Encorafenib for Metastatic Melanoma." Australian Prescriber, vol. 42, no. 5, 2019, p. 168.
Binimetinib plus encorafenib for metastatic melanoma. Aust Prescr. 2019;42(5):168.
(2019). Binimetinib plus encorafenib for metastatic melanoma. Australian Prescriber, 42(5), p. 168. doi:10.18773/austprescr.2019.057.
Binimetinib Plus Encorafenib for Metastatic Melanoma. Aust Prescr. 2019;42(5):168. PubMed PMID: 31631932.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Binimetinib plus encorafenib for metastatic melanoma. Y1 - 2019/09/13/ PY - 2019/10/22/entrez PY - 2019/10/22/pubmed PY - 2019/10/22/medline KW - Braftovi KW - Mektovi KW - binimetinib KW - encorafenib KW - metastatic melanoma SP - 168 EP - 168 JF - Australian prescriber JO - Aust Prescr VL - 42 IS - 5 SN - 0312-8008 UR - https://www.unboundmedicine.com/medline/citation/31631932/Binimetinib_plus_encorafenib_for_metastatic_melanoma L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31631932/ DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows